基于全血细胞计数和PBMV成功治疗风湿性二尖瓣狭窄的新型炎症标志物。

IF 2.1 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Biomarkers in medicine Pub Date : 2025-08-01 Epub Date: 2025-07-27 DOI:10.1080/17520363.2025.2538425

Nima Ghavamikia, Mohammad Sahebjam, Tahereh Davarpasand, Yaser Jenab

{"title":"基于全血细胞计数和PBMV成功治疗风湿性二尖瓣狭窄的新型炎症标志物。","authors":"Nima Ghavamikia, Mohammad Sahebjam, Tahereh Davarpasand, Yaser Jenab","doi":"10.1080/17520363.2025.2538425","DOIUrl":null,"url":null,"abstract":"Background: Inflammatory markers are associated with the severity of disease and outcomes in rheumatic mitral stenosis (RMS). This study explored the connection between newer inflammatory indices - specifically, the systemic immune inflammation index (SII) and systemic inflammation response index (SIRI) - and clinical outcomes in RMS patients who underwent percutaneous balloon mitral valvuloplasty (PBMV).Methods: A total of 131 patients with severe RMS who received PBMV at Tehran Heart Center between August 2015 and February 2021 were assessed. Inflammatory markers were measured prior to the procedure. Echocardiographic parameters, Wilkins scores, and complications were analyzed over a three-year follow-up period. ROC curves and multivariate logistic regression were employed to evaluate predictive associations.Results: The average age of participants was 47.9 years, and 79.4% were female. Lower systolic pulmonary pressure and younger age were associated with a greater success rate of PBMV. Frequent complications included mitral regurgitation (47.5%) and readmission (27.5%). Higher levels of NLR, MLR, SII, and SIRI were correlated with increased Wilkins scores. SIRI was an independent predictor of PBMV success.Conclusion: SIRI demonstrated the highest predictive capability for PBMV success, with 71% sensitivity and 80% specificity. It was also associated with complications and mid-term outcomes in severe RMS.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"667-675"},"PeriodicalIF":2.1000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12344811/pdf/","citationCount":"0","resultStr":"{\"title\":\"Novel inflammatory markers based on complete blood count and PBMV success in rheumatic mitral stenosis.\",\"authors\":\"Nima Ghavamikia, Mohammad Sahebjam, Tahereh Davarpasand, Yaser Jenab\",\"doi\":\"10.1080/17520363.2025.2538425\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Inflammatory markers are associated with the severity of disease and outcomes in rheumatic mitral stenosis (RMS). This study explored the connection between newer inflammatory indices - specifically, the systemic immune inflammation index (SII) and systemic inflammation response index (SIRI) - and clinical outcomes in RMS patients who underwent percutaneous balloon mitral valvuloplasty (PBMV).Methods: A total of 131 patients with severe RMS who received PBMV at Tehran Heart Center between August 2015 and February 2021 were assessed. Inflammatory markers were measured prior to the procedure. Echocardiographic parameters, Wilkins scores, and complications were analyzed over a three-year follow-up period. ROC curves and multivariate logistic regression were employed to evaluate predictive associations.Results: The average age of participants was 47.9 years, and 79.4% were female. Lower systolic pulmonary pressure and younger age were associated with a greater success rate of PBMV. Frequent complications included mitral regurgitation (47.5%) and readmission (27.5%). Higher levels of NLR, MLR, SII, and SIRI were correlated with increased Wilkins scores. SIRI was an independent predictor of PBMV success.Conclusion: SIRI demonstrated the highest predictive capability for PBMV success, with 71% sensitivity and 80% specificity. It was also associated with complications and mid-term outcomes in severe RMS.\",\"PeriodicalId\":9182,\"journal\":{\"name\":\"Biomarkers in medicine\",\"volume\":\" \",\"pages\":\"667-675\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12344811/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomarkers in medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/17520363.2025.2538425\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/27 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2025.2538425","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/27 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

摘要

背景：炎症标志物与风湿性二尖瓣狭窄（RMS）的疾病严重程度和预后相关。本研究探讨了接受经皮球囊二尖瓣成形术（PBMV）的RMS患者的新炎症指数-特别是全身免疫炎症指数（SII）和全身炎症反应指数(SIRI) -与临床结果之间的联系。方法：对2015年8月至2021年2月期间在德黑兰心脏中心接受PBMV治疗的131例严重RMS患者进行评估。手术前测量炎症标志物。超声心动图参数、威尔金斯评分和并发症在三年的随访期间进行分析。采用ROC曲线和多元逻辑回归来评估预测相关性。结果：参与者平均年龄47.9岁，女性占79.4%。较低的收缩压和较年轻的年龄与PBMV的成功率较高相关。常见并发症包括二尖瓣返流（47.5%）和再入院（27.5%）。NLR、MLR、SII和SIRI水平越高，威尔金斯评分越高。SIRI是PBMV成功的独立预测指标。结论：SIRI对PBMV成功的预测能力最高，敏感性为71%，特异性为80%。它还与严重RMS的并发症和中期预后有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Novel inflammatory markers based on complete blood count and PBMV success in rheumatic mitral stenosis.

Background: Inflammatory markers are associated with the severity of disease and outcomes in rheumatic mitral stenosis (RMS). This study explored the connection between newer inflammatory indices - specifically, the systemic immune inflammation index (SII) and systemic inflammation response index (SIRI) - and clinical outcomes in RMS patients who underwent percutaneous balloon mitral valvuloplasty (PBMV).

Methods: A total of 131 patients with severe RMS who received PBMV at Tehran Heart Center between August 2015 and February 2021 were assessed. Inflammatory markers were measured prior to the procedure. Echocardiographic parameters, Wilkins scores, and complications were analyzed over a three-year follow-up period. ROC curves and multivariate logistic regression were employed to evaluate predictive associations.

Results: The average age of participants was 47.9 years, and 79.4% were female. Lower systolic pulmonary pressure and younger age were associated with a greater success rate of PBMV. Frequent complications included mitral regurgitation (47.5%) and readmission (27.5%). Higher levels of NLR, MLR, SII, and SIRI were correlated with increased Wilkins scores. SIRI was an independent predictor of PBMV success.

Conclusion: SIRI demonstrated the highest predictive capability for PBMV success, with 71% sensitivity and 80% specificity. It was also associated with complications and mid-term outcomes in severe RMS.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Biomarkers in medicine 医学-医学：研究与实验

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.